{"title":"Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022.","authors":"Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jangho Lee, Yong-Ho Lee","doi":"10.7570/jomes24040","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As obesity increases, the burden of obesity-related comorbidities also rises. However, the prevalence of obesity-related comorbidities among individuals in Korea has not been evaluated.</p><p><strong>Methods: </strong>Data from the 2007 to 2022 Korean National Health and Nutrition Examination Surveys database were analyzed (n=93,761). The prevalence of hypertension, diabetes, dyslipidemia, steatotic liver disease (SLD), and chronic kidney disease (CKD) was analyzed based on the presence of obesity and central obesity. The prevalence of obesity-related comorbidities was examined according to age and sex.</p><p><strong>Results: </strong>The prevalence of obesity has steady increased from 31.5% in 2007-2009 to 37.4% in 2020-2022, with a more pronounced rise in men and those aged 19 to 39 years. Among individuals with obesity, the prevalence of hypertension, diabetes, dyslipidemia, CKD, and SLD has also increased. The proportion of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake have risen. The increase in CKD prevalence was particularly prominent in the young (19 to 39 years) and middle-aged (40 to 59 years) groups. Similar trends were observed when analyzing data based on central obesity.</p><p><strong>Conclusion: </strong>With the increase in obesity, the prevalence of obesity-related comorbidities in the Korean population has risen. Young and middle-aged individuals with obesity are particularly vulnerable to these comorbidities, highlighting the need for early intervention and targeted healthcare strategies.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity & Metabolic Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7570/jomes24040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: As obesity increases, the burden of obesity-related comorbidities also rises. However, the prevalence of obesity-related comorbidities among individuals in Korea has not been evaluated.
Methods: Data from the 2007 to 2022 Korean National Health and Nutrition Examination Surveys database were analyzed (n=93,761). The prevalence of hypertension, diabetes, dyslipidemia, steatotic liver disease (SLD), and chronic kidney disease (CKD) was analyzed based on the presence of obesity and central obesity. The prevalence of obesity-related comorbidities was examined according to age and sex.
Results: The prevalence of obesity has steady increased from 31.5% in 2007-2009 to 37.4% in 2020-2022, with a more pronounced rise in men and those aged 19 to 39 years. Among individuals with obesity, the prevalence of hypertension, diabetes, dyslipidemia, CKD, and SLD has also increased. The proportion of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake have risen. The increase in CKD prevalence was particularly prominent in the young (19 to 39 years) and middle-aged (40 to 59 years) groups. Similar trends were observed when analyzing data based on central obesity.
Conclusion: With the increase in obesity, the prevalence of obesity-related comorbidities in the Korean population has risen. Young and middle-aged individuals with obesity are particularly vulnerable to these comorbidities, highlighting the need for early intervention and targeted healthcare strategies.
期刊介绍:
The journal was launched in 1992 and diverse studies on obesity have been published under the title of Journal of Korean Society for the Study of Obesity until 2004. Since 2017, volume 26, the title is now the Journal of Obesity & Metabolic Syndrome (pISSN 2508-6235, eISSN 2508-7576). The journal is published quarterly on March 30th, June 30th, September 30th and December 30th. The official title of the journal is now "Journal of Obesity & Metabolic Syndrome" and the abbreviated title is "J Obes Metab Syndr". Index words from medical subject headings (MeSH) list of Index Medicus are included in each article to facilitate article search. Some or all of the articles of this journal are included in the index of PubMed, PubMed Central, Scopus, Embase, DOAJ, Ebsco, KCI, KoreaMed, KoMCI, Science Central, Crossref Metadata Search, Google Scholar, and Emerging Sources Citation Index (ESCI).